We read the article "Atrial fibrillation: a novel risk factor for no-reflow following primary percutaneous coronary intervention" by Kaya et al with interest. 1 They found that atrial fibrillation (AF) is an independent predictor of no-reflow in primary percutaneous coronary intervention). However, there were no data about the usage of antiaggregant and/or anticoagulant drugs before the procedure. There were 357 patients with AF, and all of the patients with AF has CHA2DS2-VASc (congestive heart failure, hypertension, age 75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) score 1.
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With this data, maybe this question could be answered; is there any differences about the no-reflow rates between newly diagnosed with no anticoagulants drugs or ineffective anticoagulated patients with AF and effective anticoagulated patients with AF? There were a few data about this situation.
Hale et al found that dabigatran treatment did not prevent or ameliorate the no-reflow phenomenon in a rabbit model of acute myocardial ischemia/reperfusion. 2 
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